NVSNovartis PharmaceuticalsSigning up patients
Study of Out of Specification for Tisagenlecleucel
B-cell Acute Lymphoblastic Leukemia · Diffuse Large B-cell Lymphoma
0Calmworry score, out of 100
No strong warning signs right now. The score counts warning signs; it is not a prediction.
Why this score
No warning signs right now. That's why the score is 0.
Score over time
- Stage
- Phase 3
- Patients
- 200 (planned)
- Started
- Nov 21, 2019
- Main results expected
- Mar 31, 2027
- Fully finished
- Mar 31, 2027
- Results posted
- not yet
What counts as success
The trial's main goal(s), called the “primary outcome.”
Percentage of participants with Adverse Events (AEs)
Measured over: From Screening up to 3 months for Part 1 and 1 day for Part 2
Changes Tremor has spotted
No changes since Tremor started watching this trial.
Show details (technical version)
Score inputs
- none
Raw record changes
- none yet
Trial ID NCT04094311 · record last updated 2026-09-15 · checked 2026-11-09 15:47 UTC